Mary Dibiase Sells 22,258 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Mary Dibiase sold 22,258 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $10,016.10. Following the transaction, the chief operating officer now directly owns 490,980 shares of the company’s stock, valued at $220,941. This trade represents a 4.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

X4 Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ:XFOR traded up $0.01 during trading on Monday, reaching $0.49. The company’s stock had a trading volume of 2,333,226 shares, compared to its average volume of 2,696,270. The stock has a market capitalization of $83.84 million, a PE ratio of -5.46 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 12 month low of $0.26 and a 12 month high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm’s 50 day simple moving average is $0.55 and its two-hundred day simple moving average is $0.61.

Analyst Ratings Changes

A number of brokerages recently commented on XFOR. HC Wainwright reissued a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th. Stifel Nicolaus cut their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. State Street Corp increased its position in shares of X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after buying an additional 111,032 shares during the period. Point72 Asset Management L.P. boosted its stake in X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after buying an additional 81,968 shares during the period. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals during the third quarter valued at $340,000. Finally, AQR Capital Management LLC raised its stake in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares during the period. 72.03% of the stock is owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.